EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro Assessment of Drug Adsorption Profiles during Hemoadsorption Therapy

Andreas Körtge, Christoph Kamper, Gerd Klinkmann, Reinhold Wasserkort, Steffen Mitzner

Blood Purification · 2025

DOI: 10.1159/000545120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Purification, 2025. Verfasst von Andreas Körtge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Extracorporeal Therapy Systems, Fraunhofer Institute for Cell Therapy and Immunology IZI, Rostock, Germany. Hauptthemen laut MEDLINE: Hemoperfusion, Hemofiltration. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The use of hemoadsorption devices is increasingly gaining impact as an adjunct therapy for various critical conditions in ICU patients, including systemic hyperinflammation, cytokine release syndrome, sepsis, and more. A key concern in this therapy is its impact on the plasma levels of concurrently administered drugs, which could potentially be reduced to subtherapeutic levels, affecting patient care. The present study investigates the adsorption behavior of various drugs in an in vitro hemoadsorption model using human whole blood, aiming to provide insights for optimizing drug dosing during hemoadsorption therapy.

Methods

The study assessed the removal rates and clearances of several drugs, namely, apixaban, argatroban, carbamazepine, oxcarbazepine, lamotrigine, phenytoin, valproate, levosimendan, methylene blue, and metformin, by circulating the blood through CytoSorb adsorbers in an in vitro setup.

Results

Significant removal (75 to 100% of the initial concentration) and high initial plasma clearances (approximately 10–25 mL/min) were observed for most of the tested drugs within the first 30–60 min of recirculation. Lower removal rates and clearances were noted for valproate (approximately 40% and 5 mL/min) and metformin (approximately 15% and 1 mL/min).

Conclusion

The findings indicate considerable differences in the adsorption of the tested drugs and should be confirmed by additional in vivo studies with careful monitoring of drug levels throughout the course of therapy. Understanding the in vivo dynamics is crucial for adjusting dosages appropriately during hemoadsorption use to ensure therapeutic efficacy and patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemoperfusionHemofiltrationHumansAdsorptionPharmaceutical PreparationsMetformin

Stichwörter der Autor:innen

CytoSorbDrug removalHemoadsorption

Substanzen

Pharmaceutical PreparationsMetformin

Autor:innen und Institutionen

  • Department of Extracorporeal Therapy Systems, Fraunhofer Institute for Cell Therapy and Immunology IZI, Rostock, Germany.
  • Division of Nephrology, Center for Internal Medicine, Rostock University Medical Center, Rostock, Germany.
  • Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Rostock University Medical Center, Rostock, Germany.

Zitieren

APA

Körtge, A., Kamper, C., Klinkmann, G., Wasserkort, R., & Mitzner, S. (2025). In vitro Assessment of Drug Adsorption Profiles during Hemoadsorption Therapy. Blood Purification. https://doi.org/10.1159/000545120

Vancouver

Körtge A, Kamper C, Klinkmann G, Wasserkort R, Mitzner S. In vitro Assessment of Drug Adsorption Profiles during Hemoadsorption Therapy. Blood Purification. 2025. doi:10.1159/000545120

BibTeX
@article{Krtge2025,
  author = {Körtge, Andreas and Kamper, Christoph and Klinkmann, Gerd and Wasserkort, Reinhold and Mitzner, Steffen},
  title = {In vitro Assessment of Drug Adsorption Profiles during Hemoadsorption Therapy},
  journal = {Blood Purification},
  year = {2025},
  doi = {10.1159/000545120}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche